Eisai's Leqembi Approved for Alzheimer's in Mexico

Leqembi (lecanemab), a treatment for early Alzheimer's disease developed by BioArctic AB and Eisai, has received approval from Mexico's Federal Commission for the Protection Against Sanitary Risk (COFEPRIS). This humanized monoclonal antibody works by selectively binding to soluble and insoluble amyloid-beta aggregates, reducing both protofibrils and plaques in the brain, and is the first treatment proven to slow cognitive decline in Alzheimer's patients. The approval follows successful results from the Phase 3 Clarity AD clinical trial, where Leqembi met all primary and key secondary endpoints. Approximately 1.3 million individuals in Mexico suffer from Alzheimer's disease, highlighting the potential impact of this treatment. Leqembi is already approved in several countries including the U.S., Japan, and the U.K., with Eisai and Biogen set to co-commercialize it in Mexico. This marks a significant advancement in Alzheimer's treatment options, particularly for the early stages of the disease.